You Position: Home > Paper
Has the time come for another breakthrough in surgical myocardial revascularization?
( views:65, downloads:4 )
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 2
- DOI:
- 10.3760/cma.j.issn.0366-6999.2009.02.001
- Key Word:
- No keyword available
Abstract： @@ Surgical myocardial revascularization has completed its fourth successful decade following the world's first clinical trial on coronary artery bypass grafting (CABG) in May 1967.1 Being one of the most popular and best investigated procedures in the history of surgery, CABG has stood the test of time with excellent results as measured by a variety of outcome markers. Even with the recent progress in percutaneous coronary intervention (PCI) and rapid development of intra-coronary stents (including drug-eluting stents), the advantage of CABG over PCI is likely to continue in the foreseeable future.
- [1]Kritz AB,Halliday C,George SJ,etc.In vivo modulation of nogo-B attenuates neointima formation.[J].2008,16(11).
- [2]C J, Murray,A D, Lopez.Evidence-based health policy--lessons from the Global Burden of Disease Study.[J].1996,274(5288).
- [3]F D, Loop,B W, Lytle,D M, Cosgrove,etc.Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events.[J].1986,314.
- [4]Channon KM,Black E,George SE,etc.Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production.[J].2001,104(13).
- [5]J G, Motwani,E J, Topol.Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention.[J].1998,97.
- [6]Bennett E,Ryan TJ,Walford G,etc.Long-term outcomes of coronary-artery bypass grafting versus stent implantation.[J].2005,352(21).
- [7]Bernard J, Gersh,Robert L, Frye.Methods of coronary revascularization--things may not be as they seem.[J].2005,352(21).
- [8]Drain A,Davies W,Rosengard BR,etc.A systematic review of randomized trials comparing revascularization rate and graft patency of off-pump and conventional coronary surgery.[J].2006,132(6).
- [9]Conte MS,Mann MJ,Orav EJ,etc.Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.[J].1999,354(9189).
- [10]Hafley G,Lorenz TJ,Ferguson TB Jr,etc.Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.[J].2005,294(19).
- [11]Momi S,Gresele P.Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.[J].2006,24(2).